Cell therapy development
Lyell Ronde-Cel: What the PiNACLE Response Data Show
Understand the denominator behind Lyell’s ronde-cel lymphoma response rates, safety findings, follow-up limits and implications for CAR-T trial operations.
By Lampgen Clinical Research

2 min read · estimated
What the source reported
Lyell’s November 4 disclosure reported 91% overall response and 77% complete response among 44 Day 84-evaluable patients in the third-or-later-line PiNACLE cohort. Fifty-eight patients had been treated at the June 18 cutoff. Median progression-free-survival follow-up was 12 months. No Grade 3 or higher cytokine release syndrome occurred; Grade 3 or higher ICANS was reported in 9% of treated patients.
These are single-arm findings. Ronde-cel remains investigational. A separate randomized Phase 3 study, PiNACLE-H2H, compares it with approved CD19-directed CAR-T therapies in second-line disease; the disclosed response rates do not establish that comparison.
What this means for trial teams
Lampgen’s interpretation is that the most useful operational question is how clearly the dataset explains each participant’s path. Treated, response-evaluable and safety populations serve different purposes. They should be named consistently in dashboards, presentations and site-level data review. A smaller evaluable group does not by itself establish bias or explain why people were excluded; those reasons need to be documented.
For sponsors and CROs, a practical review begins with a participant disposition table linked to the prespecified analysis rules. Study teams should reconcile infusion dates, assessment windows, missing scans, discontinuations and deaths before a cutoff. This helps reviewers distinguish assessments that are not yet due from data that are missing, unevaluable or outside a planned analysis window.
Durability adds another layer. A high response proportion and sustained disease control answer different questions. Follow-up completeness, the number of people still at risk and censoring patterns affect interpretation of time-to-event results. Teams should retain the ability to explain why follow-up ended for each participant rather than relying on one headline percentage.
The safety workflow needs equivalent discipline. Event onset, grading, interventions, resolution and hospitalization records should form a coherent timeline. A favorable result for one toxicity category does not remove the need to assess other serious events. CRAs support documentation and escalation while clinical judgments remain with investigators and medical teams.
For patients, further validation could inform future treatment choices. It is too early to claim superiority over established CAR-T options. For trial teams, the immediate implication is actionable: match monitoring capacity to assessment windows, safety reconciliation and long-term retention. These tasks determine how confidently a promising response signal can guide the next development decision.